X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2026-05-26 | RPRX | Royalty Pharma Plc | Coyne Terrance P. | EVP, CFO | S - Sale | $53.98 | -64,399 | 50,390 | -56% | -$3,476,116 | ||||||
2026-05-27 | LQDA | Liquidia Corp | Jeffs Roger | CEO | S - Sale | $62.18 | -6,428 | 2,225,770 | 0% | -$399,712 | ||||||
2026-05-26 | RIGL | Rigel Pharmaceuticals Inc | Ali-Jackson Kamil | Dir | S - Sale | $29.17 | -2,500 | 12,625 | -17% | -$72,925 | ||||||
2026-05-26 | RAPP | Rapport Therapeutics, Inc. | Third Rock Ventures V, L.P. | 10% | S - Sale | $40.05 | -18,572 | 7,249,743 | 0% | -$743,753 | ||||||
2026-05-26 | OCUL | Ocular Therapeutix, Inc | Heier Jeffrey S. | Chief Scientific Officer | S - Sale | $8.20 | -3,018 | 320,350 | -1% | -$24,748 | ||||||
2026-05-26 | OCUL | Ocular Therapeutix, Inc | Nayak Sanjay | Chief Strategy Officer | S - Sale | $8.20 | -1,858 | 328,795 | -1% | -$15,236 | ||||||
| D | 2026-05-22 | HCWB | Hcw Biologics Inc. | Wong Hing C | CEO, 10% | P - Purchase | $1.41 | +113,879 | 615,790 | +23% | +$160,000 | |||||
| D | 2026-05-22 | HCWB | Hcw Biologics Inc. | Garrett Scott T | Dir | P - Purchase | $1.41 | +177,936 | 203,441 | +698% | +$250,000 | |||||
| D | 2026-05-22 | HCWB | Hcw Biologics Inc. | Byam Rebecca | CFO | P - Purchase | $1.41 | +14,235 | 57,245 | +33% | +$20,000 | |||||
| M | 2026-05-22 | CNTN | Canton Strategic Holdings, Inc. | Stetz Gary S. | Dir | S - Sale | $3.43 | -100,351 | 134,175 | -43% | -$343,882 | |||||
| DM | 2026-05-22 | ETON | Eton Pharmaceuticals, Inc. | Krempa David | Chief Business Officer | S - Sale+OE | $32.30 | -100,000 | 25,249 | -80% | -$3,229,923 | |||||
| D | 2026-05-22 | OMER | Omeros Corp | Cable Thomas J. | Dir | S - Sale+OE | $11.61 | -7,500 | 35,067 | -18% | -$87,039 | |||||
| D | 2026-05-22 | JAZZ | Jazz Pharmaceuticals Plc | Winningham Rick E | Dir | S - Sale+OE | $241.57 | -2,741 | 9,567 | -22% | -$662,143 | |||||
2026-05-22 | JAZZ | Jazz Pharmaceuticals Plc | McSharry Heather Ann | Dir | S - Sale | $241.00 | -2,000 | 18,449 | -10% | -$482,000 | ||||||
2026-05-26 | ACAD | Acadia Pharmaceuticals Inc | Kihara James | PRINCIPAL ACCOUNTING OFFICER | S - Sale | $21.18 | -5,401 | 24,509 | -18% | -$114,393 | ||||||
2026-05-22 | ONC | Beone Medicines Ltd. | Riva Alessandro | Dir | S - Sale | $309.51 | -212 | 54,184 | 0% | -$65,617 | ||||||
2026-05-22 | ONC | Beone Medicines Ltd. | Dugan Margaret | Dir | S - Sale | $309.60 | -212 | 54,184 | 0% | -$65,636 | ||||||
2026-05-22 | ONC | Beone Medicines Ltd. | Sanders Corazon (Corsee) D. | Dir | S - Sale | $309.59 | -212 | 54,470 | 0% | -$65,633 | ||||||
2026-05-22 | ONC | Beone Medicines Ltd. | Baker Bros. Advisors LP | Dir | S - Sale | $23.82 | -10,998 | 8,962,461 | 0% | -$261,981 | ||||||
| D | 2026-05-26 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $572.94 | -10,000 | 18,876 | -35% | -$5,729,359 | |||||
| D | 2026-05-26 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $572.38 | -8,000 | 668,728 | -1% | -$4,579,018 | |||||
| D | 2026-05-26 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | P - Purchase | $575.97 | +1,500 | 668,728 | 0% | +$863,947 | |||||
| D | 2026-05-26 | NAMS | Newamsterdam Pharma Co N.V. | Kooij Louise Frederika | Chief Accounting Officer | S - Sale+OE | $35.69 | -65,000 | 24,353 | -73% | -$2,319,850 | |||||
2026-05-26 | ASND | Ascendis Pharma A/S | Bienaime Jean Jacques | Dir | P - Purchase | $237.80 | +400 | 400 | New | +$95,121 | ||||||
| D | 2026-05-26 | KALV | Kalvista Pharmaceuticals, Inc. | Yea Christopher | CHIEF DEVELOPMENT OFFICER | S - Sale+OE | $26.78 | -1,966 | 229,918 | -1% | -$52,645 | |||||
| D | 2026-05-26 | KALV | Kalvista Pharmaceuticals, Inc. | Sweeny Nicole | Chief Commercial Officer | S - Sale+OE | $26.78 | -1,489 | 59,291 | -2% | -$39,872 | |||||
| D | 2026-05-26 | KALV | Kalvista Pharmaceuticals, Inc. | Audhya Paul K. | CHIEF MEDICAL OFFICER | S - Sale+OE | $26.78 | -2,239 | 150,260 | -1% | -$59,955 | |||||
| DM | 2026-05-22 | GYRE | Gyre Therapeutics, Inc. | Ye Weiguo | COO | S - Sale+OE | $6.09 | -7,500 | 700,000 | -1% | -$45,680 | |||||
2026-05-22 | CVKD | Cadrenal Therapeutics, Inc. | Pham Quang X | CEO, COB, 10% | S - Sale | $5.69 | -1,165 | 214,924 | -1% | -$6,629 | ||||||
| D | 2026-05-21 | RCKT | Rocket Pharmaceuticals, Inc. | Shah Gaurav | CEO | S - Sale+OE | $3.09 | -55,684 | 1,467,962 | -4% | -$171,841 | |||||
| D | 2026-05-22 | KALV | Kalvista Pharmaceuticals, Inc. | Palleiko Benjamin L | CEO | S - Sale+OE | $26.78 | -10,926 | 479,989 | -2% | -$292,646 | |||||
| D | 2026-05-22 | KALV | Kalvista Pharmaceuticals, Inc. | Sweeny Nicole | Chief Commercial Officer | S - Sale+OE | $26.78 | -1,861 | 55,780 | -3% | -$49,846 | |||||
| D | 2026-05-22 | KALV | Kalvista Pharmaceuticals, Inc. | Yea Christopher | CHIEF DEVELOPMENT OFFICER | S - Sale+OE | $26.78 | -2,358 | 228,759 | -1% | -$63,158 | |||||
| D | 2026-05-22 | KALV | Kalvista Pharmaceuticals, Inc. | Audhya Paul K. | CHIEF MEDICAL OFFICER | S - Sale+OE | $26.78 | -2,685 | 147,499 | -2% | -$71,916 | |||||
| D | 2026-05-22 | KALV | Kalvista Pharmaceuticals, Inc. | Piekos Brian | CFO | S - Sale+OE | $26.78 | -1,489 | 21,661 | -6% | -$39,882 | |||||
| M | 2026-05-21 | HOWL | Werewolf Therapeutics, Inc. | Evnin Luke | Dir | S - Sale | $0.45 | -191,762 | 763,685 | -20% | -$86,560 | |||||
| D | 2026-05-21 | LQDA | Liquidia Corp | Singh Raman | Dir | S - Sale+OE | $60.13 | -29,494 | 38,755 | -43% | -$1,773,436 | |||||
| M | 2026-05-21 | LQDA | Liquidia Corp | Jeffs Roger | CEO | S - Sale | $61.01 | -75,000 | 2,232,198 | -3% | -$4,575,675 | |||||
2026-05-21 | PHVS | Pharvaris N.V. | Monges Viviane | Dir | S - Sale | $30.29 | -9,667 | 5,500 | -64% | -$292,853 | ||||||
| D | 2026-05-21 | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | CFO | S - Sale+OE | $20.42 | -9,200 | 145,355 | -6% | -$187,883 | |||||
| DM | 2026-05-21 | PHVS | Pharvaris N.V. | Nijdam Anna | Principal Accounting Officer | S - Sale+OE | $30.70 | -7,330 | 48,945 | -13% | -$225,055 | |||||
2026-05-21 | PHVS | Pharvaris N.V. | Nassif David W. | CFO , CLO | S - Sale | $30.31 | -10,000 | 120,300 | -8% | -$303,076 | ||||||
2026-05-21 | BBIO | Bridgebio Pharma, Inc. | Kumar Neil | CEO | S - Sale | $69.44 | -26,103 | 5,157,460 | -1% | -$1,812,522 | ||||||
| D | 2026-05-22 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $567.74 | -9,500 | 679,797 | -1% | -$5,393,558 | |||||
2026-05-21 | PEPG | Pepgen Inc. | Kasraian Kasra | Chief Technical Officer | S - Sale | $1.41 | -1,233 | 50,074 | -2% | -$1,739 | ||||||
| M | 2026-05-21 | SER | Serina Therapeutics, Inc. | Wilson Karen J | Dir | P - Purchase | $1.85 | +20,000 | 20,000 | New | +$37,000 | |||||
2026-05-21 | AMLX | Amylyx Pharmaceuticals, Inc. | Firestone Karen | Dir | P - Purchase | $13.51 | +3,800 | 66,900 | +6% | +$51,338 | ||||||
2026-05-22 | PRTA | Prothena Corp Public Ltd Co | Scully William P | 10% | P - Purchase | $9.81 | +100,000 | 968,000 | +12% | +$981,300 | ||||||
2026-05-21 | ZOMDF | Zomedica Corp. | Klass Russell Kevin | SVP, Sales | P - Purchase | $0.10 | +104,000 | 6,105,000 | +2% | +$10,712 | ||||||
| D | 2026-05-20 | BTAI | Bioxcel Therapeutics, Inc. | Yocca Frank | Chief Scientific Officer | S - Sale+OE | $1.09 | -6,845 | 26,175 | -21% | -$7,427 | |||||
| D | 2026-05-20 | BTAI | Bioxcel Therapeutics, Inc. | Rodriguez Javier | See Remarks | S - Sale+OE | $1.08 | -6,560 | 26,803 | -20% | -$7,111 | |||||
| D | 2026-05-20 | BTAI | Bioxcel Therapeutics, Inc. | Steinhart Richard I | CFO | S - Sale+OE | $1.09 | -6,845 | 26,300 | -21% | -$7,427 | |||||
| D | 2026-05-20 | BTAI | Bioxcel Therapeutics, Inc. | Mehta Vimal | CEO, Pres | S - Sale+OE | $1.09 | -19,419 | 550,066 | -3% | -$21,108 | |||||
| D | 2026-05-22 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $30.27 | -200,000 | 1,613,063 | -11% | -$6,054,000 | |||||
| DM | 2026-05-20 | GYRE | Gyre Therapeutics, Inc. | Ye Weiguo | COO | S - Sale+OE | $6.15 | -22,220 | 700,000 | -3% | -$136,653 | |||||
2026-05-22 | MDGL | Madrigal Pharmaceuticals, Inc. | Levy Richard S | Dir | S - Sale | $515.44 | -5,682 | 22,015 | -21% | -$2,928,716 | ||||||
2026-05-22 | ABEO | Abeona Therapeutics Inc. | Alvino Mark | Dir | S - Sale | $5.46 | -6,500 | 77,565 | -8% | -$35,463 | ||||||
| D | 2026-05-21 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $564.11 | -10,000 | 18,876 | -35% | -$5,641,130 | |||||
2026-05-19 | SER | Serina Therapeutics, Inc. | Marshall Richard Peter | Dir | P - Purchase | $1.65 | +12,183 | 12,183 | New | +$20,102 | ||||||
| D | 2026-05-21 | ORKA | Oruka Therapeutics, Inc. | Dambkowski Carl | Dir | S - Sale+OE | $58.97 | -105,000 | 73,743 | -59% | -$6,191,366 | |||||
| D | 2026-05-21 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $564.11 | -9,500 | 679,797 | -1% | -$5,359,011 | |||||
2026-05-22 | INSM | Insmed Inc | Smith Michael Alexander | GC | S - Sale | $108.47 | -6,149 | 41,613 | -13% | -$666,982 | ||||||
2026-05-21 | ARDX | Ardelyx, Inc. | Reilly Joseph James | See Remarks | S - Sale | $6.27 | -3,719 | 149,836 | -2% | -$23,309 | ||||||
2026-05-21 | ARDX | Ardelyx, Inc. | Hohenleitner Susan | CFO | S - Sale | $6.27 | -1,455 | 229,078 | -1% | -$9,119 | ||||||
2026-05-21 | ARDX | Ardelyx, Inc. | Bishop John E | See Remarks | S - Sale | $6.27 | -2,306 | 336,845 | -1% | -$14,453 | ||||||
2026-05-21 | ARVN | Arvinas, Inc. | Teel Randy | Pres, CEO | S - Sale | $9.04 | -2,209 | 285,009 | -1% | -$19,962 | ||||||
2026-05-21 | ARDX | Ardelyx, Inc. | Brady James Parker | CHRO | S - Sale | $6.27 | -1,846 | 261,066 | -1% | -$11,570 | ||||||
2026-05-21 | ARDX | Ardelyx, Inc. | Foster Eric Duane | Chief Commercial Officer | S - Sale | $6.27 | -7,998 | 417,972 | -2% | -$50,127 | ||||||
2026-05-21 | ARDX | Ardelyx, Inc. | Kelliher Mike | Chief Business Officer | S - Sale | $6.27 | -7,248 | 357,418 | -2% | -$45,427 | ||||||
2026-05-20 | DYN | Dyne Therapeutics, Inc. | Posner Brian S | Dir | P - Purchase | $17.12 | +2,500 | 18,000 | +16% | +$42,800 | ||||||
2026-05-21 | ARDX | Ardelyx, Inc. | Williams Laura A | Chief Patient Officer | S - Sale | $6.27 | -6,989 | 429,093 | -2% | -$43,804 | ||||||
2026-05-21 | ARDX | Ardelyx, Inc. | Raab Michael | Pres, CEO | S - Sale | $6.27 | -54,748 | 1,745,397 | -3% | -$343,133 | ||||||
2026-05-20 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% | P - Purchase | $64.43 | +1,563 | 505,000 | 0% | +$100,712 | ||||||
2026-05-20 | AZN | Astrazeneca Plc | Sharma Mani | See Remarks | S - Sale | $185.78 | -11,893 | 19,262 | -38% | -$2,209,482 | ||||||
| D | 2026-05-20 | PVLA | Palvella Therapeutics, Inc. | Goin Kathleen | COO | S - Sale+OE | $110.56 | -4,302 | 0 | -100% | -$475,631 | |||||
2026-05-21 | KURA | Kura Oncology, Inc. | Powl Brian T. | Chief Commercial Officer | S - Sale | $11.00 | -10,000 | 173,614 | -5% | -$110,000 | ||||||
| D | 2026-05-20 | PHVS | Pharvaris N.V. | Bjork Elisabeth | Dir | S - Sale+OE | $29.32 | -10,000 | 15,167 | -40% | -$293,166 | |||||
2026-05-21 | NATR | Natures Sunshine Products Inc | Brower Nathan G | EVP, GC | S - Sale | $21.84 | -12,015 | 43,438 | -22% | -$262,408 | ||||||
2026-05-20 | RPRX | Royalty Pharma Plc | Urist Marshall | EVP, Research, Investments | S - Sale | $52.75 | -13,684 | 37,217 | -27% | -$721,838 | ||||||
2026-05-20 | ANVS | Annovis Bio, Inc. | Hoffman Michael B | Dir | P - Purchase | $1.87 | +76,344 | 3,588,240 | +2% | +$142,779 | ||||||
| A | 2026-05-18 | AVIR | Atea Pharmaceuticals, Inc. | Murphy Polly A. | Dir | P - Purchase | $4.17 | +6,100 | 92,145 | +7% | +$25,446 | |||||
2026-05-19 | NKTR | Nektar Therapeutics | Zalevsky Jonathan | Chief R, D Officer | S - Sale | $65.51 | -199 | 20,975 | -1% | -$13,036 | ||||||
2026-05-19 | NKTR | Nektar Therapeutics | Robin Howard W | Pres, CEO | S - Sale | $65.51 | -444 | 75,073 | -1% | -$29,086 | ||||||
2026-05-19 | INM | Inmed Pharmaceuticals Inc. | Adar1 Capital Management, LLC | 10% | P - Purchase | $1.54 | +468,551 | 800,000 | +141% | +$721,548 | ||||||
| D | 2026-05-20 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $565.98 | -9,500 | 679,797 | -1% | -$5,376,814 | |||||
| D | 2026-05-21 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $562.82 | -8,300 | 45,172 | -16% | -$4,671,399 | |||||
2026-05-20 | TRDA | Entrada Therapeutics, Inc. | Zeiher Bernhardt G | Dir | P - Purchase | $5.86 | +5,000 | 5,000 | New | +$29,316 | ||||||
| M | 2026-05-18 | ZOMDF | Zomedica Corp. | Powers Johnny D | Dir | P - Purchase | $0.10 | +200,000 | 4,425,000 | +5% | +$20,600 | |||||
| M | 2026-05-20 | ZOMDF | Zomedica Corp. | Klass Russell Kevin | Sr. Vice President, Sales | P - Purchase | $0.11 | +216,899 | 6,001,000 | +4% | +$22,797 | |||||
2026-05-19 | RCKT | Rocket Pharmaceuticals, Inc. | Shah Gaurav | CEO | S - Sale | $3.01 | -2,409 | 1,447,156 | 0% | -$7,261 | ||||||
2026-05-19 | RCKT | Rocket Pharmaceuticals, Inc. | Wilson Martin | GC | S - Sale | $3.01 | -662 | 677,977 | 0% | -$1,995 | ||||||
2026-05-19 | RCKT | Rocket Pharmaceuticals, Inc. | Militello John | See Remarks | S - Sale | $3.01 | -384 | 89,780 | 0% | -$1,157 | ||||||
2026-05-13 | ANL | Adlai Nortye Ltd. | Lu Yang | CEO, 10% | S - Sale | $13.18 | -10 | 99,990 | 0% | -$132 | ||||||
2026-05-19 | RNXT | Renovorx, Inc. | Voll Mark | CFO | P - Purchase | $0.79 | +25,000 | 239,580 | +12% | +$19,690 | ||||||
2026-05-19 | LQDA | Liquidia Corp | Caligan Partners LP | See Remarks, 10% | S - Sale | $59.98 | -5,300 | 16,290,998 | 0% | -$317,894 | ||||||
2026-05-19 | LQDA | Liquidia Corp | Caligan Partners LP | See Remarks, 10% | P - Purchase | $59.98 | +5,300 | 16,290,998 | 0% | +$317,894 | ||||||
| M | 2026-05-18 | RLYB | Rallybio Corp | Adar1 Capital Management, LLC | 10% | P - Purchase | $13.98 | +16,209 | 926,352 | +2% | +$226,563 | |||||
2026-05-18 | IRD | Opus Genetics, Inc. | Foundation Fighting Blindness Retinal Degeneration Fund | See Remarks | S - Sale | $4.35 | -1,700,000 | 3,792,171 | -31% | -$7,395,000 | ||||||
| M | 2026-05-18 | LQDA | Liquidia Corp | Jeffs Roger | CEO | S - Sale | $58.91 | -75,000 | 2,307,198 | -3% | -$4,418,010 | |||||
| M | 2026-05-18 | HOWL | Werewolf Therapeutics, Inc. | Evnin Luke | Dir | S - Sale | $0.45 | -171,049 | 955,447 | -15% | -$76,363 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |